Bodo Möller Chemie expands portfolio with new Life Sciences business Strategic move in the IMEA region

Bodo Möller Chemie Group announces the launch of its new Life Sciences business in the IMEA region, which includes the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, Bahrain, Lebanon, Jordan, Iraq, and Egypt. This strategic move marks a significant expansion for Bodo Möller Chemie, adding a further major business line alongside its established Formulated Systems and Industrial Raw Materials divisions.

The new Life Sciences business will offer a comprehensive portfolio of raw materials and ingredients for the human nutrition, pharmaceuticals, personal care, home care, and industrial and institutional care sectors. Bodo Möller Chemie aims to provide innovative solutions and technical support with lab services, emphasizing close customer and supplier relationships and operational efficiency. Frank Haug, CEO of Bodo Möller Chemie Group, comments, “With the launch of our Life Sciences business in the IMEA region, we are ready to meet the growing demand for high-quality raw materials and chemicals. This initiative represents a new strategic dimension for our company, allowing us to diversify and strengthen our position in the Middle East market.”

“The Middle East region is witnessing major initiatives to increase local production levels and self-sufficiency, particularly in the pharmaceutical, food, and care sectors. Bodo Möller Chemie’s in-depth market knowledge and industry expertise positions it as a key player in this transformation,” states Abdallah Dabaghi, Executive Vice President IMEA. The company’s comprehensive market coverage, supported by its local offices and warehouses in the area, enables it to provide tailored solutions and technical support through its qualified sales and technical teams. “As a complexity reducer and solutions provider, we are committed to offering a diversified product portfolio, qualified technical support, and superior logistics services,” concludes Haug. “Our entry into the life sciences market in the IMEA region is a significant milestone that is in line with our long-term vision and strategic goals.”.